ABT logo

Abbott Laboratories (ABT) Cash and cash equivalents

annual cash & cash equivalents:

$7.62B+$720.00M(+10.44%)
December 31, 2024

Summary

  • As of today (June 22, 2025), ABT annual cash & cash equivalents is $7.62 billion, with the most recent change of +$720.00 million (+10.44%) on December 31, 2024.
  • During the last 3 years, ABT annual cash & cash equivalents has fallen by -$2.18 billion (-22.28%).
  • ABT annual cash & cash equivalents is now -59.10% below its all-time high of $18.62 billion, reached on December 31, 2016.

Performance

1-year change

+10.44%

3-year change

-22.28%

5-year change

+97.31%

15-year change

-19.04%

ABT Cash and cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

99.03%
ABT annual cash & cash equivalents is higher than 99.03% of companies in Healthcare sector

Range

All-time high

$18.62B
ABT annual cash & cash equivalents is currently -59.10% below its historical high of $18.62 billion

3-year low

$6.90B
ABT annual cash & cash equivalents is currently +10.44% above its 3-year low

Earnings dates

Last annual earnings report date

Dec 31, 2024
ABT previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
ABT next annual earnings announcement has not yet been scheduled

OtherABTbalance sheet metrics

quarterly total assets

$81.45B
ABT quarterly total assets is $81.45 billion

quarterly current assets

$23.15B
ABT quarterly total current assets is $23.15 billion

quarterly total liabilities

$32.38B
ABT quarterly total liabilities is $32.38 billion

quarterly current liabilities

$13.00B
ABT quarterly total current liabilities is $13.00 billion

quarterly cash & cash equivalents:

$6.53B-$1.08B(-14.23%)
March 1, 2025

Summary

  • As of today (June 22, 2025), ABT quarterly cash & cash equivalents is $6.53 billion, with the most recent change of -$1.08 billion (-14.23%) on March 1, 2025.
  • Over the past year, ABT quarterly cash & cash equivalents has increased by +$248.00 million (+3.95%).
  • ABT quarterly cash & cash equivalents is now -64.92% below its all-time high of $18.62 billion, reached on December 31, 2016.

Performance

3-month change

-14.23%

1-year change

+3.95%

3-year change

-14.89%

5-year change

+93.43%

ABT quarterly cash & cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

98.95%
ABT quarterly cash & cash equivalents is higher than 98.95% of companies in Healthcare sector

Range

All-time high

$18.62B
ABT quarterly cash & cash equivalents is currently -64.92% below its historical high of $18.62 billion

3-year low

$6.28B
ABT quarterly cash & cash equivalents is currently +3.95% above its 3-year low

Earnings dates

Last quarterly earnings report date

Mar 1, 2025
ABT previous earnings announcement was published on Mar 1, 2025

Next quarterly earnings report date

Jul 18, 2025
ABT next earnings announcement is scheduled for Jul 18, 2025

OtherABTbalance sheet metrics

quarterly total assets

$81.45B
ABT quarterly total assets is $81.45 billion

quarterly current assets

$23.15B
ABT quarterly total current assets is $23.15 billion

quarterly total liabilities

$32.38B
ABT quarterly total liabilities is $32.38 billion

quarterly current liabilities

$13.00B
ABT quarterly total current liabilities is $13.00 billion

Cash and cash equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

ABT Cash and cash equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+10.4%+4.0%
3 y3 years-22.3%-14.9%
5 y5 years+97.3%+93.4%

ABT Cash and cash equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-22.9%+10.4%-33.9%+4.0%
5 y5-year-22.9%+97.3%-33.9%+93.4%
alltimeall time-59.1%>+9999.0%-64.9%>+9999.0%

ABT Cash and cash equivalents History

DateAnnualQuarterly
Mar 2025
-
$6.53B(-14.2%)
Dec 2024
$7.62B(+10.4%)
$7.62B(+0.8%)
Sep 2024
-
$7.56B(+8.2%)
Jun 2024
-
$6.99B(+11.2%)
Mar 2024
-
$6.28B(-8.9%)
Dec 2023
$6.90B(-30.2%)
$6.90B(+2.8%)
Sep 2023
-
$6.71B(-14.4%)
Jun 2023
-
$7.83B(-14.5%)
Mar 2023
-
$9.16B(-7.3%)
Dec 2022
$9.88B(+0.8%)
$9.88B(+3.0%)
Sep 2022
-
$9.59B(+7.4%)
Jun 2022
-
$8.94B(+16.4%)
Mar 2022
-
$7.67B(-21.7%)
Dec 2021
$9.80B(+43.3%)
$9.80B(+5.3%)
Sep 2021
-
$9.30B(+7.4%)
Jun 2021
-
$8.66B(+7.5%)
Mar 2021
-
$8.05B(+17.8%)
Dec 2020
$6.84B(+77.2%)
$6.84B(+52.6%)
Sep 2020
-
$4.48B(-5.9%)
Jun 2020
-
$4.76B(+41.0%)
Mar 2020
-
$3.38B(-12.5%)
Dec 2019
$3.86B(+0.4%)
$3.86B(-5.6%)
Sep 2019
-
$4.09B(+30.4%)
Jun 2019
-
$3.14B(+3.8%)
Mar 2019
-
$3.02B(-21.4%)
Dec 2018
$3.84B(-59.1%)
$3.84B(-47.8%)
Sep 2018
-
$7.37B(+140.4%)
Jun 2018
-
$3.06B(-20.5%)
Mar 2018
-
$3.86B(-59.0%)
Dec 2017
$9.41B(-49.5%)
$9.41B(-14.6%)
Sep 2017
-
$11.01B(+13.8%)
Jun 2017
-
$9.68B(+11.1%)
Mar 2017
-
$8.71B(-53.2%)
Dec 2016
$18.62B(+272.3%)
$18.62B(+644.8%)
Sep 2016
-
$2.50B(-3.0%)
Jun 2016
-
$2.58B(-22.7%)
Mar 2016
-
$3.33B(-33.3%)
Dec 2015
$5.00B(+23.1%)
$5.00B(+59.7%)
Sep 2015
-
$3.13B(-22.6%)
Jun 2015
-
$4.05B(+25.5%)
Mar 2015
-
$3.23B(-20.6%)
Dec 2014
$4.06B(+16.9%)
$4.06B(+12.5%)
Sep 2014
-
$3.61B(+1.2%)
Jun 2014
-
$3.57B(+73.3%)
Mar 2014
-
$2.06B(-40.7%)
Dec 2013
$3.48B(-67.8%)
$3.48B(+20.6%)
Sep 2013
-
$2.88B(-48.3%)
Jun 2013
-
$5.57B(+27.4%)
Mar 2013
-
$4.37B(-59.5%)
Dec 2012
$10.80B(+58.6%)
$10.80B(+35.1%)
Sep 2012
-
$8.00B(+13.4%)
Jun 2012
-
$7.05B(+62.3%)
Mar 2012
-
$4.35B(-36.2%)
Dec 2011
$6.81B(+86.7%)
$6.81B(+34.9%)
Sep 2011
-
$5.05B(+23.8%)
Jun 2011
-
$4.08B(+48.8%)
Mar 2011
-
$2.74B(-24.9%)
Dec 2010
$3.65B(-58.6%)
$3.65B(-4.4%)
Sep 2010
-
$3.82B(-11.7%)
Jun 2010
-
$4.32B(+175.8%)
Mar 2010
-
$1.57B(-82.2%)
Dec 2009
$8.81B(+114.2%)
$8.81B(+80.7%)
Sep 2009
-
$4.88B(+16.0%)
Jun 2009
-
$4.20B(-13.8%)
Mar 2009
-
$4.87B(+18.5%)
Dec 2008
$4.11B(+67.4%)
$4.11B(+46.3%)
Sep 2008
-
$2.81B(-26.0%)
Jun 2008
-
$3.80B(+40.1%)
Mar 2008
-
$2.71B(+10.3%)
Dec 2007
$2.46B(+371.3%)
$2.46B(+28.6%)
Sep 2007
-
$1.91B(+24.2%)
Jun 2007
-
$1.54B(+125.5%)
Mar 2007
-
$682.35M(+30.9%)
DateAnnualQuarterly
Dec 2006
$521.19M(-82.0%)
$521.19M(-1.0%)
Sep 2006
-
$526.37M(-33.4%)
Jun 2006
-
$790.90M(-66.2%)
Mar 2006
-
$2.34B(-19.0%)
Dec 2005
$2.89B(+136.1%)
$2.89B(+1.7%)
Sep 2005
-
$2.85B(+96.6%)
Jun 2005
-
$1.45B(-15.0%)
Mar 2005
-
$1.70B(+39.0%)
Dec 2004
$1.23B(+23.2%)
$1.23B(+51.1%)
Sep 2004
-
$810.89M(-34.2%)
Jun 2004
-
$1.23B(+9.6%)
Mar 2004
-
$1.12B(+12.9%)
Dec 2003
$995.12M(+41.3%)
$995.12M(-40.8%)
Sep 2003
-
$1.68B(+55.9%)
Jun 2003
-
$1.08B(+5.7%)
Mar 2003
-
$1.02B(+44.9%)
Dec 2002
$704.45M(+7.2%)
$704.45M(-5.1%)
Sep 2002
-
$742.65M(+54.0%)
Jun 2002
-
$482.14M(-49.0%)
Mar 2002
-
$944.98M(+43.8%)
Dec 2001
$657.38M(-28.1%)
$657.38M(+10.6%)
Sep 2001
-
$594.15M(-10.6%)
Jun 2001
-
$664.75M(+35.1%)
Mar 2001
-
$492.19M(-46.2%)
Dec 2000
$914.22M(+50.3%)
$914.22M(+4.1%)
Sep 2000
-
$878.12M(+4.5%)
Jun 2000
-
$840.15M(+23.4%)
Mar 2000
-
$680.89M(+12.0%)
Dec 1999
$608.10M(+92.9%)
$608.10M(+14.5%)
Sep 1999
-
$531.07M(+53.6%)
Jun 1999
-
$345.78M(-1.7%)
Mar 1999
-
$351.76M(+11.6%)
Dec 1998
$315.20M(+37.0%)
$315.20M(+41.0%)
Sep 1998
-
$223.47M(-11.2%)
Jun 1998
-
$251.77M(+11.6%)
Mar 1998
-
$225.54M(-1.9%)
Dec 1997
$230.00M(+108.7%)
$230.00M(+77.7%)
Sep 1997
-
$129.40M(+2.3%)
Jun 1997
-
$126.52M(-5.6%)
Mar 1997
-
$134.09M(+21.7%)
Dec 1996
$110.20M(-60.8%)
$110.20M(-21.2%)
Sep 1996
-
$139.90M(+25.5%)
Jun 1996
-
$111.48M(+26.8%)
Mar 1996
-
$87.92M(-68.7%)
Dec 1995
$281.20M(-3.1%)
$281.20M(-12.3%)
Sep 1995
-
$320.80M(+26.1%)
Jun 1995
-
$254.40M(+38.1%)
Mar 1995
-
$184.21M(-36.5%)
Dec 1994
$290.27M(-3.5%)
$290.27M(+30.7%)
Sep 1994
-
$222.03M(+22.9%)
Jun 1994
-
$180.60M(+5.6%)
Mar 1994
-
$171.06M(-43.1%)
Dec 1993
$300.68M(+157.9%)
$300.68M(+118.2%)
Sep 1993
-
$137.80M(+367.1%)
Jun 1993
-
$29.50M(-42.7%)
Mar 1993
-
$51.50M(-55.8%)
Dec 1992
$116.60M(+93.0%)
$116.60M(+328.7%)
Sep 1992
-
$27.20M(-29.2%)
Jun 1992
-
$38.40M(+70.7%)
Mar 1992
-
$22.50M(-62.7%)
Dec 1991
$60.40M(+77.6%)
$60.40M(+22.0%)
Sep 1991
-
$49.50M(-14.2%)
Jun 1991
-
$57.70M(+6.3%)
Mar 1991
-
$54.30M(+59.7%)
Dec 1990
$34.00M(+150.0%)
$34.00M(-71.1%)
Sep 1990
-
$117.50M(+225.5%)
Jun 1990
-
$36.10M(-52.9%)
Mar 1990
-
$76.60M(+463.2%)
Dec 1989
$13.60M(-97.7%)
$13.60M(-97.7%)
Dec 1988
$582.60M(+12.1%)
$582.60M(+12.1%)
Dec 1987
$519.90M(+8.0%)
$519.90M(+8.0%)
Dec 1986
$481.60M(+10.1%)
$481.60M(+10.1%)
Dec 1985
$437.50M(-2.1%)
$437.50M(-2.1%)
Dec 1984
$447.10M
$447.10M

FAQ

  • What is Abbott Laboratories annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Abbott Laboratories?
  • What is Abbott Laboratories annual cash & cash equivalents year-on-year change?
  • What is Abbott Laboratories quarterly cash & cash equivalents?
  • What is the all time high quarterly cash & cash equivalents for Abbott Laboratories?
  • What is Abbott Laboratories quarterly cash & cash equivalents year-on-year change?

What is Abbott Laboratories annual cash & cash equivalents?

The current annual cash & cash equivalents of ABT is $7.62B

What is the all time high annual cash & cash equivalents for Abbott Laboratories?

Abbott Laboratories all-time high annual cash & cash equivalents is $18.62B

What is Abbott Laboratories annual cash & cash equivalents year-on-year change?

Over the past year, ABT annual cash & cash equivalents has changed by +$720.00M (+10.44%)

What is Abbott Laboratories quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of ABT is $6.53B

What is the all time high quarterly cash & cash equivalents for Abbott Laboratories?

Abbott Laboratories all-time high quarterly cash & cash equivalents is $18.62B

What is Abbott Laboratories quarterly cash & cash equivalents year-on-year change?

Over the past year, ABT quarterly cash & cash equivalents has changed by +$248.00M (+3.95%)
On this page